Ground report

Two medical conditions form major obstacles to India's kala azar elimination plan

HIV co-infections increase the risk of kala azar. A non-fatal but contagious form of kala azar also poses a significant challenge.

Through most of July, August and September, 34-year-old Krishna Kumar* had been ill with fever. Kumar drives trailers in Haryana and is on the road almost all year, going home to Motihari district in Bihar for a few days every five or six months.

“I would keep going to doctors on the road but I could not get rid of the fever,” said Kumar.

On his last visit home, Kumar consulted a private doctor who diagnosed him with kala azar and sent him to the district hospital. Here, as guidelines set out in 2014 for all patients with kala azar, Kumar was tested for HIV and his results showed that he was HIV-positive.

Doctors at the Motihari district hospital sent Kumar to the Rajendra Memorial Research Institute of Medical Sciences, Patna. This institute, along with Médecins Sans Frontiers, has been conducting a clinical trial on the effectiveness of a treatment protocol with a higher dose of Liposomal Amphotericin B, the new drug that has vastly simplified treatment of kala azar.

Kala azar, or visceral leishmaniasis as is its scientific name, is caused by a leishmania parasite transmitted by the female sand fly. It is characterised by irregular bouts of fever, weight loss, enlargement of the spleen and liver that gives the patient a pot belly, and anaemia. If left untreated for more than two years, it is almost certainly fatal.

HIV-kala azar co-infection and post-dermal kala azar leishmaniasis, a skin presentation of kala azar often abbreviated to PKDL, are serious threats to the government’s ambitions of eliminating kala azar by 2017. Bihar has about 70% of the total kala azar cases in the country. The other states where the disease is significant are Jharkhand, West Bengal and Uttar Pradesh.

Consumptive co-infections

HIV and kala azar are mutually reinforcing infections, which means that HIV-infected people are vulnerable to kala azar, while kala azar advances an HIV infection.

“Both kala azar and HIV are immunosuppressants,” said Dr Ravinder Singh Rishi, the medical team leader for a kala azar-HIV co-infection treatment study with Médecins Sans Frontiers. "Treatment relapse rate [in case of an HIV co-infection] is almost 100-1,200 times higher than the treatment rate of kala azar without complications.”

Many patients with co-infections suffer from severe acute malnutrition due to which their immunity is already low. Kala azar is considered a consumptive disease that leads to wastage of the body and pulls immunity levels further down.

When Scroll.in visited the Patna institute on August 29, there were two kala azar patients with HIV and tuberculosis co-infections. Both suffered severe acute malnutrition, which is very low weight for height. Both were confined to an isolation room so that they would not spread tuberculosis to other low-immunity patients in the ward.

Difficult to detect

A Médecins Sans Frontières study conducted in Hajipur city’s district hospital in Bihar in 2014 showed that 5.6% of kala azar patients had HIV too. This number is much higher than the HIV prevalence of 0.37%, as recorded by the National Aids Control Organisation in their 2015-'16 report. Nearly 40% to 50% of patients with kala azar and HIV co-infection do not know their HIV status, which makes them very vulnerable to the disease since they would not not receive anti-HIV treatment.

Things get more complicated with kala azar being difficult to detect in HIV-positive people. Kala azar is normally diagnosed using the rk-39 dipstick test, which can detect the infection with a drop of blood obtained by pricking a finger and is 99% accurate. The same test is less effective in HIV co-infected kala azar patients, who instead need to undergo bone marrow aspiration to check for kala azar.

Despite the known risks of co-infection, antiretroviral therapy centres in Bihar often do not look for symptoms of kala azar. In addition, most government health establishments do not refer kala azar patients for HIV tests despite guidelines issued in 2014 to that effect. Kumar in Motihari was one of the few patients who was tested for HIV after being diagnosed with kala azar.

“It is like finding a needle in a haystick,” said Rishi. Médecins Sans Frontières plans to conduct an awareness campaign among laboratory technicians, district government hospitals, primary health care centres, private doctors and other facilitators to test for HIV among patients with kala azar.

In the next few months, the non-profit will start this campaign in seven Bihar districts where kala azar is endemic – Vaishali, Darbanga, Muzaffarpur, Samastipur, Siwan, Gopalganj and Motihari.

Difficult to treat

Unlike the single dose Liposomal Amphotericin B treatment given in a day for HIV-negative kala azar, HIV-positive patients are given eight doses over a period of 24 days. Treatment failure and relapse rates are very high with various treatment protocols. Most patients will, therefore, continue to be infectious.

So far, no treatment protocol has been effective on a large scale in treating people with kala azar-HIV co-infections.

Liposomal Amphotericin B is known to work in a small group of HIV patients in Bihar but with a higher risk of relapse and death. The study conducted by Médecins Sans Frontières found that antiretroviral treatment initiated after kala azar treatment is known to reduce risk of relapse and mortality. Yet, the risk of relapse and death remained a significant 25.9% and 29.7 %, respectively, after two and four years of treatment.

"The earlier study had given only 20-25 mg per/kg of Liposomal Amphotericin B," explained Dr Gaurab Mitra, medical activity manager, Médecins Sans Frontières. "In the new one, we are giving 40 mg per kg of the drug in eight doses to the patients. We are also comparing this protocol to another one, with Liposomal Amphotericin B and miltefosene oral drugs."

The new study hopes to have a better protocol for treatment of HIV-kala azar co-infection patients. "We do not have a good protocol yet for these patients," he said.

The skin infection version

Another possible threat to the grand kala azar elimination plan is a condition called post kala azar dermal leishmaniasis, more commonly referred to as PKDL or cutaneous leishmaniasis.

PKDL patients have visible lesions or discolouration of the skin. The Kala Azar Elimination Programme considers PKDL a threat as patients are said to be reservoirs of the parasite leishmaniasis.

Some studies show that the nodular lesions are a blood meal for sandflies, which infect them when they bite. The sandflies, in turn, infect other humans. PKDL is reported in patients with a history of kala azar, where the rashes appear on the face and other parts of the body.

“Around 95% of PKDL cases have a history of kala azar,” said Dr Nupur Roy, additional director of the National Vector Borne Disease Control Programme. “These are parasites not cleared by antibiotics, as they may not reach under the skin. The skin has less supply of blood as compared to the rest of the body.”

Unlike HIV-kala azar co-infections, the challenge here is not to find the patients or treatment failures but a lack of incentive to patients to get treated. PKDL is non-fatal and causes little pain and discomfort. Doctors in the public health system, therefore, find it difficult to convince patients to spend time and money on treatment.

Why treatment?

Take the case of 10-year old Preeti Kumari, a resident of Bhagwatpur village in Samastipur distict in Bihar. Kumari was on her way to school when Mukesh Singh stopped her and asked her if she had been to the nearby public health centre in Sarairanjan block. Singh is the Samastipur district programme manager with New Concept, which is part of KalaCore – a consortium of organisations that is now on a mission to control and eliminate the disease by 2017.

In 2015, Kumari had suffered a bout of kala azar and had been treated for it. After treatment, she developed rashes on her face, hands and neck that looked like small discoloured spots. She was suspected to have been suffering from PKDL.

In June, after a communication programme in Kumari’s school, the New Concept team had identified possible PKDL carriers and asked them to get tested. “We went to the Sarairanjan Primary Health Centre mid-June," Kumari’s mother Poonam Devi told Singh. "They told us that the kits are not available. We did not go after that.”

“Why did you not go after a few days?” Singh asked.

Devi, a single mother who takes care of the home and works in the fields to bring in money to feed her family, gave him a resigned look.

Kumari's schoolmate, seven-year-old Sharda, also had spots on her body and was referred to the primary health centre. Her parents had made no effort to get a diagnosis.

The biggest barrier for treatment is the fact that only two facilities – the Rajendra Memorial Research Institute of Medical Sciences in Patna and the Kala Azar Research Institute in Muzaffarpur – give reliable diagnoses of PKDL. The treatment mostly lasts 12 weeks, often with the oral drug miltefosine, and sometimes a combination of other drugs. The patient has to visit the hospital every month.

The treatment has side effects. Twelve-year-old Shubham from Bajitpur village in Samastipur has spots on his face and body and was diagnosed with PKDL in August. He had to be taken to the Patna institute to get treatment, which takes more than two hours in a bus.

“His stomach hurts and he feels nauseous, giddy and vomits often," said his mother Munni Devi. "He has been told not to be exposed to sunlight, but it is difficult to stop a child from playing.” Shubham had not gone to school in over a month.

Finally, PKDL gets attention

About 10% of people treated for kala azar cases in Bihar are now being detected with PKDL. This year, 361 cases of PKDL have been recorded in the state so far.

In the past, chronic PKDL cases in interepidemic periods have been implicated in the upsurge of visceral leishmaniasis epidemics in the Indian subcontinent and Sudan.

While the focus of the Kala Azar Elimination Programme is detection and treatment of kala azar cases, the government for the first time is also tracking PKDL. This year, the Bihar government too started recording cases of PKDL.

“PKDL was earlier not included in the elimination programme," said Roy. "The patient would not be bothered to get treated, as the treatment is for a long duration. Even physicians felt that why should we be treating this disease at all.”

Though the numbers of both PKDL and HIV-kala azar patients are few, their treatment is important, feel experts.

Mitra said, "Since the government is on an elimination mode, it needs to take in all arms of the problem, including PKDL and HIV-kala azar co-infection, into consideration. Otherwise there will be no elimination."

Public health problem

The only reason to send a person with a non-fatal condition that does not bother him for treatment that has uncomfortable side-effects is if the existence of the condition poses a real public health problem.

In 1980, Dr A Nandy and his associate from the Calcutta School of Tropical Medicine conducted a study too try and determine whether PKDL patients can infect sandflies, who in turn can infect other healthy people. Sandflies were allowed to bite four patients with PKDL. A significant number of sandflies were found with the parasite in their guts.

However, this evidence is being reassessed now by Dr Shyam Sunder from Benaras Hindu University, who has conducted some of the most important research on kala azar. “PKDL-sandfly infection studies are on," he said in an email to Scroll.in. "Thus far, there is no evidence, or little evidence.”

Some research even shows that the most common form of PKDL among Indians is less likely to infect sandflies.

Recently, scientists from the Rajendra Memorial Research Institute of Medical Sciences in Patna conducted a study to test whether PKDL patients infect sandflies among 400 patients. “Most of our patients have a macular form of PKDL, not other mixed infections such as nodular or papular,” explained Dr Pradeep Das, the director of the insitute.

While macular PKDL is mostly characterised by discolouration of the skin, papular PKDL consists of an elevated lesion and and nodular PKDL is a small elevated mass of tissue. In the papular and nodular forms of PKDL, the parasite can be found in the skin, said Das.

“This is usually characterised by skin depigmentation," said Das. "Among these patients, only 40% have the parasite under the skin, which makes it less likely that the sandfly becomes infected. The hypothesis that PKDL transmits the disease in a big way may not be correct.”

Should the programme be designed in a way that only nodular and papular PKDL patients be sent for treatment? Das felt that the government should not bother treating patients with macular PKDL. “We should not waste any drug [since patients do not need it] as it could create resistance in society," he said.

*Names of HIV-positive people have been changed to protect their identity.

This reporting project has been made possible partly by funding from the New Venture Fund for Communications project, which receives support from the Bill & Melinda Gates Foundation.

We welcome your comments at letters@scroll.in.
Sponsored Content BY 

Relying on the power of habits to solve India’s mammoth sanitation problem

Adopting three simple habits can help maximise the benefits of existing sanitation infrastructure.

India’s sanitation problem is well documented – the country was recently declared as having the highest number of people living without basic sanitation facilities. Sanitation encompasses all conditions relating to public health - especially sewage disposal and access to clean drinking water. Due to associated losses in productivity caused by sickness, increased healthcare costs and increased mortality, India recorded a loss of 5.2% of its GDP to poor sanitation in 2015. As tremendous as the economic losses are, the on-ground, human consequences of poor sanitation are grim - about one in 10 deaths, according to the World Bank.

Poor sanitation contributes to about 10% of the world’s disease burden and is linked to even those diseases that may not present any correlation at first. For example, while lack of nutrition is a direct cause of anaemia, poor sanitation can contribute to the problem by causing intestinal diseases which prevent people from absorbing nutrition from their food. In fact, a study found a correlation between improved sanitation and reduced prevalence of anaemia in 14 Indian states. Diarrhoeal diseases, the most well-known consequence of poor sanitation, are the third largest cause of child mortality in India. They are also linked to undernutrition and stunting in children - 38% of Indian children exhibit stunted growth. Improved sanitation can also help reduce prevalence of neglected tropical diseases (NTDs). Though not a cause of high mortality rate, NTDs impair physical and cognitive development, contribute to mother and child illness and death and affect overall productivity. NTDs caused by parasitic worms - such as hookworms, whipworms etc. - infect millions every year and spread through open defecation. Improving toilet access and access to clean drinking water can significantly boost disease control programmes for diarrhoea, NTDs and other correlated conditions.

Unfortunately, with about 732 million people who have no access to toilets, India currently accounts for more than half of the world population that defecates in the open. India also accounts for the largest rural population living without access to clean water. Only 16% of India’s rural population is currently served by piped water.

However, there is cause for optimism. In the three years of Swachh Bharat Abhiyan, the country’s sanitation coverage has risen from 39% to 65% and eight states and Union Territories have been declared open defecation free. But lasting change cannot be ensured by the proliferation of sanitation infrastructure alone. Ensuring the usage of toilets is as important as building them, more so due to the cultural preference for open defecation in rural India.

According to the World Bank, hygiene promotion is essential to realise the potential of infrastructure investments in sanitation. Behavioural intervention is most successful when it targets few behaviours with the most potential for impact. An area of public health where behavioural training has made an impact is WASH - water, sanitation and hygiene - a key issue of UN Sustainable Development Goal 6. Compliance to WASH practices has the potential to reduce illness and death, poverty and improve overall socio-economic development. The UN has even marked observance days for each - World Water Day for water (22 March), World Toilet Day for sanitation (19 November) and Global Handwashing Day for hygiene (15 October).

At its simplest, the benefits of WASH can be availed through three simple habits that safeguard against disease - washing hands before eating, drinking clean water and using a clean toilet. Handwashing and use of toilets are some of the most important behavioural interventions that keep diarrhoeal diseases from spreading, while clean drinking water is essential to prevent water-borne diseases and adverse health effects of toxic contaminants. In India, Hindustan Unilever Limited launched the Swachh Aadat Swachh Bharat initiative, a WASH behaviour change programme, to complement the Swachh Bharat Abhiyan. Through its on-ground behaviour change model, SASB seeks to promote the three basic WASH habits to create long-lasting personal hygiene compliance among the populations it serves.

This touching film made as a part of SASB’s awareness campaign shows how lack of knowledge of basic hygiene practices means children miss out on developmental milestones due to preventable diseases.

Play

SASB created the Swachhata curriculum, a textbook to encourage adoption of personal hygiene among school going children. It makes use of conceptual learning to teach primary school students about cleanliness, germs and clean habits in an engaging manner. Swachh Basti is an extensive urban outreach programme for sensitising urban slum residents about WASH habits through demos, skits and etc. in partnership with key local stakeholders such as doctors, anganwadi workers and support groups. In Ghatkopar, Mumbai, HUL built the first-of-its-kind Suvidha Centre - an urban water, hygiene and sanitation community centre. It provides toilets, handwashing and shower facilities, safe drinking water and state-of-the-art laundry operations at an affordable cost to about 1,500 residents of the area.

HUL’s factory workers also act as Swachhata Doots, or messengers of change who teach the three habits of WASH in their own villages. This mobile-led rural behaviour change communication model also provides a volunteering opportunity to those who are busy but wish to make a difference. A toolkit especially designed for this purpose helps volunteers approach, explain and teach people in their immediate vicinity - their drivers, cooks, domestic helps etc. - about the three simple habits for better hygiene. This helps cast the net of awareness wider as regular interaction is conducive to habit formation. To learn more about their volunteering programme, click here. To learn more about the Swachh Aadat Swachh Bharat initiative, click here.

This article was produced by the Scroll marketing team on behalf of Hindustan Unilever and not by the Scroll editorial team.